[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-rhinosinusitis-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-rhinosinusitis-diagnosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,40,70,93,113,136,162,192,214,236,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100472116","phase-2-topical-probiotic-sinus-irrigations-for-treating-chronic-sinusitis-100472116",false,"NCT05427695","Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis","Topical Probiotic Sinus Irrigations for the Treatment of Chronic Rhinosinusitis: a Double Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n1. Male and female patients 18 years of age or older.\n2. Patients diagnosed with acute exacerbation of CRS, defined by worsening of 1 or more sinonasal symptoms (nasal obstruction\u002Fcongestion, nasal discharge, facial pain\u002Fpressure, reduced sense of smell) and inflammatory and\u002For infectious changes on sinus endoscopy.\n3. Patients that have undergone functional endoscopic sinus surgery \\> 12 months prior to enrollment as documented in the patients electronic medical record, with patent sinuses deemed suitable for trial on investigator's discretion.\n4. Patients must be willing to follow study related procedures for the duration of the study.\n5. Patients must understand the purpose and procedures and be willing to sign the study informed consent document.\n6. All adult men and women with active CRS will be considered for participation in this study without regard to race, gender, or socioeconomic status.\n\nExclusion Criteria:\n\n1. Patients who are taking topical antibiotic irrigations and are unwilling to stop them.\n2. Patients who are unable to complete self-administered questionnaires because of cognitive impairment, language barrier, or severe medical conditions.\n3. Patients who have a terminal illness (malignancy), immunocompromised (medication-related immunosuppression, immunodeficiency disorder) or systemic disease (granulomatosis polyangiitis or other autoimmune disease with sinonasal manifestations, cystic fibrosis), or recent head\u002Fsinonasal trauma that may predispose to infectious complications.\n4. Patients who have severe or emergent complications from CRS or presence of a sinus tumor.\n5. Female patients who are pregnant or breastfeeding. The patient will be asked if she is pregnant or has any chance of being pregnant. In either case, the patient will be excluded. Note in our consent form this is also addressed (excerpt below).\n6. Patients who are taking oral corticosteroids or who have taken oral antibiotics in the previous 2 weeks or on oral corticosteroids.\n7. Patients who have upper respiratory infection-type symptoms at time of enrollment, e.g., fevers\u002Fchills, sneezing, runny nose, sore throat, coughing. Patients can be eligible for enrollment once symptoms have fully resolved if all other inclusion\u002Fexclusion criteria are met.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this randomized study will be to determine whether topical probiotic sinus irrigations are more effective compared to saline sinus irrigation controls in the treatment of active CRS in patients who have had prior sinus surgery based on subjective and objective outcome measures.",[26],"Chronic Rhinosinusitis (Diagnosis)","RECRUITING","2026-05-21",{"date":30,"type":31},"2026-05-27","ACTUAL",{"date":33,"type":31},"2025-02-05",{"date":35,"type":20},"2028-07-30",{"name":37,"class":38},"University of Illinois at Chicago","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100530811","sinus-disease-in-young-children-with-cystic-fibrosis-100530811","NCT06191640","Sinus Disease in Young Children With Cystic Fibrosis","Inclusion Criteria:\n\nHEMT Group:\n\n* Children with documentation of a CF diagnosis\n* Age 2-8 years old at first study visit\n* CFTR mutation consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor)\n* Clinician intent to prescribe ivacaftor or ETI so that enrollment is before start of HEMT\n\nNon-HEMT\u002FControl Group:\n\n* Children with documentation of a CF diagnosis\n* Age 2-8 years at first study visit\n* Ineligible for highly effective modulator therapy (ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor) based on CFTR mutation or clinical decision not to initiate HEMT if eligible\n\nExclusion Criteria:\n\nFor Both Groups:\n\n* Use of an investigational drug within 28 days prior to the first study visit\n* Use of ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor within the 180 days prior to and including the first study visit\n* Use of chronic oral corticosteroids within the 28 days prior to and including the first study visit.\n* Sinus surgery within 180 days prior to the first study visit","2 Years","8 Years",{"count":49,"type":20},80,"OBSERVATIONAL","This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Outcomes will include sinus magnetic resonance imaging (MRI) scans, olfactory tests, and quality of life surveys obtained over a two-year period.",[53,54,26,55,56],"Cystic Fibrosis in Children","Cystic Fibrosis","Olfactory Disorder","Olfactory Impairment",[54,58,59],"Chronic Rhinosinusitis","Olfactory Dysfunction","2026-05-06",{"date":62,"type":31},"2026-05-11",{"date":64,"type":31},"2023-04-12",{"date":66,"type":20},"2029-06-30",{"name":68,"class":38},"University of California, Los Angeles",6,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100398538","impact-of-sinus-surgery-on-individuals-with-cystic-fibrosis-100398538","NCT04469439","Impact of Sinus Surgery on Individuals With Cystic Fibrosis","The Impact of Sinus Surgery in the Era of Highly Effective Modulatory Therapy","Inclusion Criteria:\n\n1. Subjects between the ages of 18 years old (inclusive) and 99 years old (inclusive, subjects over the age of 89 will be recorded to be 89 years old).\n2. Diagnosed with cystic fibrosis as established by genetic testing combined with clinical assessment and\u002For sweat chloride\n3. Diagnosed with chronic rhinosinusitis by multidisciplinary sinusitis guidelines\n4. chronic rhinosinusitis symptoms persisting beyond initial medical treatment\n5. Counseled for endoscopic sinus surgery and ongoing medical therapy with each patient electing their preferred treatment\n\nExclusion Criteria:\n\n1. Underwent endoscopic sinus surgery in past 12 months\n2. Will obtain follow up care at non-participating institutions\n3. Unable to complete follow-up surveys","99 Years",{"count":79,"type":20},170,"This study will be a prospective, observational study of patients who undergo endoscopic sinus surgery for cystic fibrosis-related chronic rhinosinusitis (CRS). Individuals who do not undergo surgery but are treated medically for CRS will also be enrolled to serve as a control group. Outcomes analyzed will include pulmonary, quality of life, and others.",[26,54],[58,54,83],"Endoscopic Sinus Surgery","2026-04-17",{"date":86,"type":31},"2026-04-22",{"date":88,"type":31},"2020-07-01",{"date":90,"type":20},"2027-01-31",{"name":68,"class":38},9,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":39},"100319523","early-phase-1-ivacaftor-for-acquired-cftr-dysfunction-in-chronic-rhinosinusitis-100319523","NCT03439865","Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis","Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (Randomized Pilot Study Utilizing Ivacaftor for the Treatment of Refractory Gram-Negative Bacterial CRS)","Inclusion Criteria:\n\n* 18 years of age\n* Patient has provided informed consent\n* Diagnosis of CRS made by one of the investigators\n* Standard of care CT scan with definitive demonstration of isolated or diffuse mucosal thickening, bone changes, and air fluid levels, obtained within 30 days of treatment\n* Positive culture of at least one gram negative bacteria (e.g. Pseudomonas, E. coli, Steenotrophomonas) within 30 days prior to testing\n* Previous surgery with (at least) exposed maxillary and ethmoid sinuses\n* Ability to perform EDSPD testing such that nasal cavity space and sinus openings are sufficient for catheter placement\n* Negative pregnancy test for females of childbearing potential within 72 hours of testing and start of study treatment\n\nExclusion Criteria:\n\n* \\\u003C 18 years of age\n* Acute illness other than sinusitis within 2 weeks before start of study treatment that, in the opinion of the investigator, would preclude participation\n* Currently taking medications that are moderate or strong CP3A inhibitors\n* History of asthma attack requiring emergency room visit or treatment with oral steroids within 2 months prior to study treatment\n* History of solid organ or hematological transplantation\n* History of known immunodeficiency, autoimmune or granulomatous disorder\n* Serum creatinine \\> 1.5x upper normal limit\n* Abnormal liver function, as defined by serum AST \\> 2x upper normal limit, serum ALT \\> 2x upper normal limit, Alkaline phosphatase \\> 2x upper normal limit, Total bilirubin \\> 2x upper normal limit\n* Women who are pregnant or breastfeeding",{"count":101,"type":20},20,[103],"EARLY_PHASE1","The purpose of this pilot study is to explore wither ivacaftor in refractory CRS patients will demonstrate safety and tolerability; restore CFTR-mediated Cl- secretions as measured by EDSPD testing; produce detectable improvements in validated measures of CRS including the SNOT-22 questionnaire, Lund-MacKay CT scan grading, and Lund-Kennedy endoscopic scores; and provide beneficial effects on readily measured markers of sinonasal inflammation and infection (IP-10, IL-8, and Pseudomonas CFUs).",[26],{"date":86,"type":31},{"date":108,"type":31},"2019-05-02",{"date":110,"type":20},"2027-05-01",{"name":112,"class":38},"University of Alabama at Birmingham",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100508094","early-phase-1-the-role-of-il5-in-epithelial-cell-integrity-100508094","NCT05895929","The Role of IL5 in Epithelial Cell Integrity","Inclusion Criteria:\n\n* (1) sinonasal inflammation for greater than 12 weeks which include at least 2 of the following symptoms: nasal obstruction\u002Fcongestion, nasal discharge (anterior or posterior), facial pressure\u002Fpain, reduction of sense of smell.\n* (2) confirmation of the clinical symptoms by: (2a) CT scan evidence of paranasal sinus mucosal inflammation, and\u002For (2b) endoscopic exam evidence of purulence from the sinuses or ostiomeatal complex; and\n* (3) presence of nasal polyps seen on endoscopic exam or sinus CT scan.\n\nExclusion Criteria:\n\n* 1\\. Children under the age of 18 will be excluded due to:\n\n  1. possible confounding diagnosis of cystic fibrosis and other non-Type 2 inflammatory etiologies that commonly presents with nasal polyps in the pediatric population.\n  2. lack of complete pneumatization of the majority of paranasal sinuses\n* 2\\. pregnant or lactating females,\n* 3\\. prisoners,\n* 4\\. mentally disabled\n* 5\\. persons unable to give informed consent will be contemplated for inclusion.\n* 6\\. disease secondary to a clearly defined anatomic process, such as facial trauma, and obstruction due to sinonasal neoplasm.\n* 7\\. exposure to oral or systemic IV glucocorticoids within 2 weeks of surgery\n* 8\\. exposure to immunomodulatory biologics will be excluded. These include, but are not limited to systemic treatment with biologics omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab, or rituximab.","100 Years",{"count":121,"type":20},8,[103],"The goal of this laboratory study is the examine the effect of mepolizumab drug on the health and function of the cells lining the human nasal airways in vitro cell culture derived from patients with chronic rhinosinusitis with nasal polyposis. The main questions the study aims to study are:\n\n1. To see what mepolizumab does to suppress inflammation of the human cells.\n2. To see what mepolizumab does to maintain barrier integrity of epithelial cells",[125,26],"Chronic Rhinosinusitis With Nasal Polyps","2026-01-09",{"date":128,"type":31},"2026-01-12",{"date":130,"type":31},"2023-09-05",{"date":132,"type":20},"2026-06",{"name":134,"class":38},"Johns Hopkins University",2,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":39},"100591915","effect-of-photobiostimulation-versus-pulsed-electromagnetic-field-on-quality-of-life-in-adults-with-chronic-rhinosinusitis-100591915","NCT06986629","Effect of Photobiostimulation Versus Pulsed Electromagnetic Field on Quality of Life in Adults With Chronic Rhinosinusitis","Inclusion Criteria:\n\n1. Participants suffering from mild to moderate symptoms (baseline Total nasal symptoms score ≤ 9).\n2. Subjects age range from 20 to 40 years old.\n3. Patients of both sexes.\n4. proven positive allergy test (skin prick test or multiple allergen simultaneous test) to any of the common perennial allergens such as dust mites, molds, insects, and animal dander within the last 12 months\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Patients with a definite deviated nasal septum, or history of operation within the last 6 months.\n* Hypertension, diabetes mellitus, malignancy, active pulmonary tuberculosis, active respiratory disease like asthma, or other systemic diseases.\n* Long-term use of corticosteroids or immunosuppressive agents.\n* Participation in another clinical study within 30 days.\n* Hyperthyroidism\n* Patients who had used antihistamines within 1 week, topical corticosteroids within 2 weeks, systemic corticosteroids within 4 weeks, anticholinergic drugs within 3 days, antileukotriene drugs within 1 week, decongestants within 3 days, tricyclic antidepressants or phenothiazines within 2 weeks, nonsteroidal analgesics within 2 weeks, and other drugs that the researchers believed were inappropriate.\n* Patients with Tattoos, moles and dark skin","20 Years","40 Years",{"count":19,"type":20},[146],"NA","This study was done to find out the effect of photobiostimulation and pulsed electromagnetic field in patients with chronic rhinosinusitis on:\n\n* Quality of life.\n* Pulmonary function.\n* Mean platelet volume.\n* headache .\n* total nasal symptoms.",[149,150,151,26,152],"Photobiostimulation","Pulsed Electromagnetic Filed","Low Level Laser Therapy","Quality of Life","2025-05-15",{"date":155,"type":31},"2025-05-23",{"date":157,"type":31},"2025-02-01",{"date":159,"type":20},"2025-08-01",{"name":161,"class":38},"Cairo University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":173,"conditions":174,"keywords":177,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":39},"100440012","moving-towards-precision-medicine-in-united-airways-disease-unraveling-inflammatory-patterns-in-asthmatic-patients-with-or-without-nasal-polyps-100440012","NCT05009758","Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps","Moving Towards PREcision Medicine In United Airways Disease: Unraveling inflaMmatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM) - a Descriptive Pilot Study","PREMIUM","Inclusion Criteria:\n\nAll patients who\n\n* 18-99 years of age\n* have a recorded clinical diagnosis of asthma (ICD-10 Code: J45)\n* undergo moderate-serve asthma treatment according to GINA\u002FDAL treatment step 4 or step 5 without oral corticosteroid or monoclonal antibody therapy\n* Asthma treatment for a minimum of 12 weeks prior to screening visit\n\n  * Group 1 and 2 - T2-high asthma with or without polyps:\n* FeNO \\> 25 ppB\n* had either two times \\>= 250 eosinophils \u002Fµl measured in the blood OR one measurement of blood eosinophils \\>= 250 cells\u002Fµl (one of the two measurements at the screening visit) and\u002For one measurement of sputum eosinophils \\> 2% within the last 12 months\n* Group with polyps: Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)\n\n  * Group 3 - CRSwNP in absence of asthma:\n* Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines\n* Evidence of Type 2 inflammation: eosinophils \\>= 250 cells\u002Fµl measured in the blood OR total IgE \\>100 kU\u002FL at the screening visit\n* Absence of asthma and N-ERD\n* Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a wash out period of 5 half-lives or at least 3 months have passed\n\nExclusion Criteria:\n\n* Pregnancy (as determined by ß-HCG test)\n* Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity\n* Patients undergoing chronic oral corticosteroid therapy\n* Patients with any other confounding underlying lung disorder including but not limited to:\n\n  * Bronchiectasis, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, emphysema, primary ciliary dyskinesia\n  * Cystic fibrosis, any known parasitic infections, and lung cancer\n* Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia including but not limited to: Eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillus, and hypereosinophilic syndrome\n* A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study\n* Patients with clinically meaningful comorbidity as determined by the evaluating committee\n* Patients with a history of exacerbation of chronic rhinosinusitis or asthma 4 weeks prior to any visit\n* Intake of a burst of systemic corticosteroids 4 weeks prior to any visit.\n* Immunosuppressive treatment (e.g. cyclosporine)\n* Drug and alcohol abuses\n* Current smoker\n* Former smoker if stopped smoking \\\u003C6 months and\u002For has \\>10 pack-years",{"count":171,"type":20},30,[146],"Asthma and chronic rhinosinusitis (CRS) are inflammatory diseases of the respiratory tract, asthma from the lower part, and CRS, from the upper part. In theory, these parts are correlated as if they are one single organ, namely \"united airways\", which means that if one is affected by any condition, the other might be impacted as well. However, this relationship has not yet been described down to the cellular and molecular levels. By investigating patients that have (1) asthma and CRS with nasal polyp, (2) asthma and CRS without nasal polyp, and (3) just CRS with nasal polyp, we aim to determine the correlation of the upper and lower part of the respiratory tract. At first, the characterization of disease will be determined by established clinical criteria, such as lung function, blood analysis for the presence of eosinophils (a type of white cells), and nasal polyp score. To continue, in-depth analysis of nose, oropharynx, and lung samples will help gain information about the inflammatory profile and local microbiome of the three different groups of patients through molecular and cellular assays. The results of this study will help to describe the hypothesis of the united airways which will provide better guidance for medical treatment of asthma and CRS with or without polyp, thus improving the life quality of patients.",[175,125,26,176],"Asthma","Nasal Polyps",[175,178,179,180,181,182],"Chronic Rhinosinusitis (CRS)","CRS with Nasal Polyps","CRS without Nasal Polyps","Inflammatory profile","Type 2 inflammation","2025-05-06",{"date":185,"type":31},"2025-05-07",{"date":187,"type":31},"2021-09-01",{"date":189,"type":20},"2026-12",{"name":191,"class":38},"Medical University of Vienna",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":200,"studyType":50,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":213},"100413944","real-life-chronic-rhinosinusitis-outcome-registry-100413944","NCT04670172","Real-Life Chronic Rhinosinusitis Outcome Registry","Inclusion Criteria:\n\n* Physician diagnosis of Chronic RhinoSinusitis\n* Capable of using a mobile application on a smartphone\n\nExclusion Criteria:\n\n* Patients with malignancies of the sinonasal cavity\n* Patients with inverted papilloma\n* Patients with unilateral disease",{"count":199,"type":20},4550,"3 Years","An international consortium of leading medical experts in the field of chronic respiratory disease, the research team of Galenus Health and the non-profit organization EUFOREA (European Forum for Research and Education in Allergy and Airway diseases) has been conceived to conduct real-life outcome research. The Galenus Health digital platform consisting of a mobile application for patients and an online dashboard for physicians will be implemented in each of the participating centres. The data will be centralized in a pseudonymized database and will be the basis of the Chronic RhinoSinusitis Outcome Registry.",[26],"2025-02-11",{"date":205,"type":31},"2025-02-13",{"date":207,"type":31},"2021-01-01",{"date":209,"type":20},"2025-12-31",{"name":211,"class":212},"Change Accelerator in Respiratory Care","INDUSTRY",13,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":21,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100507093","phase-2-the-effect-of-intra-sinus-application-of-betamethasone-dipropionate-nasal-cream-on-patients-with-chronic-rhinosinusitis-post-functional-endoscopic-sinus-surgery-fess-100507093","NCT05882903","The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients with Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery (FESS)","Inclusion Criteria:\n\n* Adult patients with a clinically confirmed diagnosis of CRS by an otolaryngologist (ENT) undergoing maximal medical therapy as part of their standard of care.\n* Having undergone functional endoscopic sinus surgery (FESS) at least 6 months prior to enrolment.\n* For each nostril, an endoscopic nasal polyp score of 0, 1, or 2 out of a maximum score of - (where 0= No polyps, 1= small polyps in the middle meatus not reaching below the inferior border of the middle turbinate , 2= nasal polyps reaching below the border of the middle turbinate, 3= large nasal polyps reaching the lower border of the inferior turbinate or nasal polyps medial to the middle turbinate, 4= large nasal polyps causing almost complete obstruction of the inferior nasal cavity) (Gevaert et al, 2023).\n* Visible middle turbinates and access to the ethmoid sinuses for dosing as established via endoscopic examination.\n* Participants must have a \\> 2 on the disease severity visual analogue scale (VAS) at screening and pre-treatment.\n* Body weight: A minimum body weight \\>=40 kilograms (kg) and a BMI of ≤ 39 at the screening visit.\n* Individuals of childbearing potential must use adequate birth control methods and not plan to get pregnant during the study.\n* Informed consent: Willingness to give written informed consent and willingness to participate in and comply with the study.\n* Age ≥18 but \\\u003C80 years.\n\nExclusion Criteria:\n\n* Subjects with known hypersensitivity or contraindications to betamethasone dipropionate, mometasone, or topical anaesthesia.\n* Subjects with sino-nasal abnormalities, disease, or implanted devices that prevents the application of the therapy.\n* Previous enrolment in this study.\n* Subjects currently receiving systemic corticosteroid or have received systemic corticosteroid in the prior 4 weeks or receiving biologic therapy.\n* Subjects with a history of glaucoma or cataracts or have an abnormal intraocular pressure (IOP) at screening or pre-treatment (abnormal IOP is defined as greater than 21 mm Hg).\n* Subjects with acute sinusitis.\n* Subjects with known immunodeficiency.\n* Subjects with diabetes (Type 1).\n* Subjects with cystic fibrosis.\n* Pregnant subjects or subjects trying to get pregnant or currently lactating as the effect on human pregnancy is unknown.\n* Subjects who are unable to give an informed consent because of mental illness, dementia or communication difficulties.\n* Subjects with a Cushing's disease diagnosis within the previous 12 months.\n* Severe septal deviation and or previous total resection of the middle turbinate.\n* Any lab abnormality or underlying medical condition which, in the Investigator's opinion, should exclude the participant.\n* Subjects who are unlikely to comply with study procedures, restrictions and requirements as determined by the investigator.","80 Years",{"count":222,"type":20},24,[23],"To assess the safety and efficacy of one (single) application of Betamethasone Dipropionate Nasal Cream (BMDP CREAM) onto the sinus mucosa.",[26],"2024-11-10",{"date":228,"type":31},"2024-11-12",{"date":230,"type":31},"2023-08-17",{"date":232,"type":20},"2025-06-01",{"name":234,"class":212},"Oticara Australia PTY LTD",4,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":21,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":252,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100554677","comparative-analysis-of-silastic-stenting-in-sinus-surgery-100554677","NCT06502197","Comparative Analysis of Silastic Stenting in Sinus Surgery","Comparative Analysis of Short-term (4 Weeks) vs. Long-term (12 Weeks) Silastic Stenting in Frontal Sinus Surgery: A Prospective Study of Clinical Outcomes","Inclusion Criteria:\n\n* Patients diagnosed with chronic rhinosinusitis requiring Frontal drill-out.\n\nExclusion Criteria:\n\n* Patients unwilling or unable to comply with the study protocol.\n* Previous Radiotherapy to operated area.","19 Years","89 Years",{"count":246,"type":20},100,[146],"Silastic stenting is a measure taken to support tissue healing following sinus surgery. Silastic stents are inserted into the sinus cavities and provide structural support while facilitating healing in the critical period of recovery following surgery. There is controversy over the optimal duration for which silastic stents should be left in place. Having them in place for shorter periods may reduce the likelihood of stent-related reactions, while leaving them for longer periods could promote more tissue healing. The aim of this study is to compare the impact of stent duration on clinical outcomes of patients following sinus surgery.",[26],[251],"Chronic Rhinosinusitis, Endoscopic Sinus Surgery, Silastic Stenting","NOT_YET_RECRUITING","2024-07-09",{"date":255,"type":31},"2024-07-16",{"date":257,"type":20},"2024-09-02",{"date":259,"type":20},"2026-03-02",{"name":261,"class":38},"University of British Columbia",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":269,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":272,"studyType":50,"phases":4,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":39},"100443970","the-nasal-microbiome-and-its-importance-in-disease-100443970","NCT05061329","The Nasal Microbiome and Its Importance in Disease","The Importance of the Nasal Microbiome in Transmission and Disease","Inclusion Criteria:\n\nExclusion Criteria:\n\n* Does not wish to participate in study",true,{"count":271,"type":20},619,"6 Months","Methods: all studies are case control studies on six different groups: normal individuals, non-COVID-19 patients with olfactory dysfunction, COVID-19 positive patients, previous COVID-19 positive patients with prolonged olfactory dysfunction, patients with chronic rhinosinusitis with and without nasal polyps, and patients with CRS initiating intranasal glucocorticoids.. The patients will be included from the ear-, nose, and throat department and the University Clinic for Flavour, Balance, and Sleep Regional Hospital Gødstrup, as well as Flavour Institute, Department of Clinical Medicine, Aarhus University (AU), and the long COVID-19 clinics in Aarhus and Gødstrup.\n\nMicrobiome samples will be swabs from the nasal cavity and oral pharynx will be collected and analysed using next-generation sequencing targeting 16S and 18S ribosomal RNA at the Department of Bacteria, Parasite \\& Fungi at Staten Serum Institute (SSI), Copenhagen, Denmark. Characterization of the microbiome is performed by 16S\u002F18S amplicon-based metagenomics, and data are analyzed by various bio-informatic tools for determination\u002Fvisualization of alpha\u002Fbeta diversity as well as principal coordinates analysis (PCoA). Immunological factors will be collected by means of six swabs: in the nasal cavity and used for either flowcytometry or enzyme-linked immunosorbent assay (ELISA).\n\nFor comparison, truecut biopsies of the nasal mucosa are collected from a subgroup of patients undergoing surgery in general anaesthesia.\n\nDue to the novelty of the current study, little relevant information from previous literature can be used for power calculation. However, with an alpha of 5% and a power of 80%, the population size for each group should be 42 participants, assuming the occurrence of bacteria differs with 30% between populations. Taking 20% drop out into account, the investigators aim to include 60 patients in each group.\n\nPerspectives:\n\nThe perspectives of this study is to begin bridging the gap between gut and upper airway microbiome and immunology research. Looking at the explosion of interest in the gut, and in personalized medicine in general, the investigators likewise foresee a huge potential for both general and individual prevention and treatments starting with a deeper understanding of the nasal microbiome and immunology. Examples beyond the scope of this study could be microbiome transplants for chronic sufferers of diseases such as chronic rhinosinusitis, allergies or asthma, or in selecting which patients could reap the benefits of the expensive biological treatments emerging on the market.",[26,275,276],"COVID-19","Anosmia","2023-11-30",{"date":279,"type":31},"2023-12-07",{"date":281,"type":31},"2020-12-21",{"date":283,"type":20},"2026-12-31",{"name":285,"class":38},"University of Aarhus"]